Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.43
- Piotroski Score 2.00
- Grade N/A
- Symbol (SILO)
- Company Silo Pharma, Inc.
- Price $1.08
- Changes Percentage (1.89%)
- Change $0.02
- Day Low $1.04
- Day High $1.10
- Year High $4.50
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.17
- Trailing P/E Ratio -2.1
- Forward P/E Ratio -2.1
- P/E Growth -2.1
- Net Income $-3,700,683
Income Statement
Quarterly
Annual
Latest News of SILO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
EssilorLuxottica And Meta Platforms Double Down On Smart Eyewear: Details
Ray-Ban and Meta's collaboration since 2019 has resulted in two generations of smart glasses, blending style and technology. The glasses are in high demand across various markets, with EssilorLuxottic...
By Yahoo! Finance | 1 week ago -
EssilorLuxottica expands smart glasses partnership with Meta
(Reuters) - EssilorLuxottica said on Tuesday it will extend its long-standing partnership with Meta Platforms to continue the development of smart eyewear into the next decade. "The incredible wor...
By Reuters | 1 week ago -
The recent 15% gain must have brightened CEO Silong Chen's week, Dogness (International) Corporation's (NASDAQ:DOGZ) most bullish insider
Analyzing a company's past performance and ownership structure can provide insights into its future performance. For example, Dogness (International) Corporation is largely owned by individual insider...
By Yahoo! Finance | 2 weeks ago